Side effects of exemplary clinical trials testing epigenetic inhibitors in cancer treatment
| Drug | Tumour entity | Side effects | References |
|---|---|---|---|
| AN-9 (butyric acid prodrug) | Melanoma, lung cancer, leukaemia | Moderate vomiting, fever, nausea and fatigue, mild elevation of hepatic transaminase, hyperglycaemia, transient visual toxicity, combination with docetaxel resulted in severe toxicity | 28 87 |
| Valproic acid | Leukaemia, myelodysplasia, cervical cancer | Neurological toxicity, bone pain, delayed haematological recovery | 88 89 |
| Vorinostat (plus paclitaxel plus carboplatin) | NSCLC | Febrile neutropenia, asthenia, diarrhoea, thrombocytopenia compared with the placebo group (paclitaxel+carboplatin+placebo) | NCT00473889 |
| Panobinostat | Hodgkin’′s lymphoma, multiple myeloma | Thrombocytopenia, vomiting, diarrhoea, headache and abdominal pain more frequent compared with the placebo group, no significant increase of side effects when combined with bortezomib | NCT01034163, NCT01023308 |
| CI-994 (plus gemcitabine) | Pancreatic cancer | Increased neutropaenia and thrombocytopenia compared with placebo group | 42 |
| BI-2536 | Pancreatic cancer | Neutropenia, thrombocytopenia, leucopenia, fatigue | 90 |
NSCLC, non-small cell lung cancer.